Phospho-HER2/ErbB2 Antibody Sampler Kit

• 产品编号：CST-9923S      品牌：Cell Signaling Technology       原厂货号：9923S
• 产品分类：抗体 > 一抗 > 复合抗体试剂盒
• 应用分类：

其它组分：

描述：

每一个磷酸化HER2/ErbB2抗体仅仅识别HER2/ErbB2在特定位点的磷酸化形式。HER2/ErbB2受体对照抗体则既可以识别HER2/ErbB2的磷酸化形式，也可以识别非磷酸化形式。多克隆抗体是通过用合成的磷酸化多肽免疫动物而生成，该磷酸化多肽与Tyr1248位点周围的残基序列一致。多抗的纯化采用蛋白A和多肽亲和层析法进行。单克隆抗体是通过用合成的多肽免疫动物而生成，这些多肽与人ErbB2蛋白靠近氨基末端的残基以及酪氨酸1221/1222周围的残基序列一致。磷酸化HER2/ErbB2抗体小包装试剂盒为检测HER2/ErbB2的活化状态提供了一种经济的方式，包括检测Tyr1248 和 Tyr1221/1222位点的磷酸化。用于对照的HER2/ErbB2抗体也包括在试剂盒内。这个试剂盒包含了足够做四次WB实验的一抗。

原癌基因ErbB2 (HER2)编码185kDa的受体样跨膜糖蛋白，该蛋白具有酪氨酸激酶的活性 (4)。ErbB2的配体目前尚不清楚，但在过表达的ErbB2与其它ErbB家族成员形成异源二聚体时，即使缺少配体，其酶活性仍能被激活(5)。将近40%的人类乳腺癌中能够检测到ErbB2基因的扩增及其产物的过量表达（6）。ErbB2的主要自磷酸化位点是Tyr1248和 Tyr1221/1222，这些位点的磷酸化将ErbB2与Ras-Raf-MAP激酶的信号转导途径联系起来(4,7)。

原癌基因ErbB2 (HER2)编码185kDa的受体样跨膜糖蛋白，该蛋白具有固有的酪氨酸激酶的活性 (1)。ErbB2的配体目前尚不清楚，但在高表达的ErbB2与其它ErbB家族成员形成异源二聚体时，即使缺少配体，其酶活性仍能被激活(2)。将近40%的人类乳腺癌中能够检测到ErbB2基因的扩增及其产物的过量表达。泛素连接酶c-Cbl结合在ErbB2的Tyr1112上能够导致ErbB2聚泛素化并促进其降解(4)。ErbB2是乳腺癌等多种癌肿的关键治疗靶点，通过c-Cbl介导的蛋白水解途径靶向调控ErbB2的降解是一种潜在的治疗手段。磷酸化ErbB2的激酶位点Tyr877（同源于pp60c-Src 的Tyr416）能调控ErbB2的生物活性。ErbB2的自磷酸化位点是Tyr1248和 Tyr1221/1222，这些位点的磷酸化将ErbB2与Ras-Raf-MAP激酶的信号转导途径联系起来(1,5)。

1. Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.
2. Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.
3. Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.
4. Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.
5. Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.

原厂资料：

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1248. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding tyrosines 1221/1222 and residues near the amino terminus of human ErbB2 protein.

Description

The Phospho-HER2/ErbB2 Antibody Sampler Kit provides an economical means to evaluate the activation status of HER2/ErbB2, including the phosphorylation of Tyr1248 and Tyr1221/1222. The control HER2/ErbB2 antibody is also included. The kit contains enough primary antibodies to perform four Western blot experiments per primary antibody.

Background

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).

1. Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.
2. Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.
3. Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.
4. Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.
5. Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibodies.